GSK Is Eyeing $55 Billion In Sales — And It Has Nothing To Do With Obesity

GSK Stock Soars To 12-Year High On Bullish Views That Have Nothing To Do With Obesity | Investor's Business DailyTRENDING: [How To Handle The Current Market]---GSK (GSK) stock catapulted to a 12-year high Wednesday after the U.K.-based drugmaker said it expects sales in five years' time to approach $55 billion. This will come despite not having a GLP-1 drug in the red-hot weight-loss space. "I think it's going to be very crowded," Chief Executive Luke Miels told reporters early Wednesday, according to BioSp ...